Omada Health (OMDA) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
7 Aug, 2026Executive summary
Achieved record quarterly revenue of $88 million in Q2 2026, up 43% year-over-year, with total members up 45% and gross margin reaching 73%; net income was $5 million, reversing a prior year loss, and adjusted EBITDA reached $11 million.
Leadership transition announced: President Wei-Li Shao to become CEO in January 2027, with founder Sean Duffy moving to Executive Chair.
Expanded partnerships, notably with HCSC, and launched a standalone cholesterol care track and new prescribing program, with first customer revenue expected in 2027.
Q2 capped an exceptional first half of 2026, with broad-based growth across programs and channels.
Operating expenses increased due to investments in R&D, sales and marketing, and general and administrative functions to support growth.
Financial highlights
Q2 2026 revenue reached $88 million, up from $61 million in Q2 2025, representing 43% year-over-year growth; gross margin expanded to 73% (GAAP) and 74% (non-GAAP).
Net income was $5 million in Q2 2026, compared to a net loss of $5 million in Q2 2025; adjusted EBITDA was $11 million, up from a loss of $0.2 million.
Cash and cash equivalents stood at $222 million as of June 30, 2026, with no debt.
Gross profit for the quarter was $63.8 million, up 58% year-over-year.
Weighted-average diluted shares outstanding for the quarter were 63.9 million.
Outlook and guidance
Raised full-year 2026 revenue guidance to $334–$340 million, implying about 30% growth over 2025; adjusted EBITDA guidance increased to $21–$27 million, about four times 2025 results at the midpoint.
Expect growth rate to moderate in the second half due to seasonality, with next major enrollment inflection in 2027.
Early evidence of market demand for new prescribing offerings, with first customer closed and revenue anticipated in 2027.
Investments will continue in technology, Care Team efficiency, and new program offerings, including GLP-1 prescribing capabilities.
Current liquidity is expected to be sufficient to fund operations for at least the next 12 months.
Latest events from Omada Health
- Record revenue and margin gains driven by product expansion and channel partnerships.OMDA
Canaccord Genuity's 46th Annual Growth Conference - 52% revenue growth and new GLP-1 prescribing drive expansion and margin gains.OMDA
44th Annual J.P. Morgan Healthcare Conference - Directors and auditor were elected and ratified, with 70% quorum and results to be filed.OMDA
AGM 2026 - Record Q1 growth and margins reflect durable, tech-driven care and expanding clinical solutions.OMDA
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Q1 2026 revenue up 42%, members up 51%, margin expansion, and raised outlook on PBM and clinical gains.OMDA
Q1 2026 - Shareholders will vote on director elections and auditor ratification, with strong governance and oversight.OMDA
Proxy filing - Vote to elect two directors and ratify Deloitte & Touche LLP as auditor at the June 2026 meeting.OMDA
Proxy filing - 53% revenue growth, margin expansion, and new programs set up strong 2026 outlook.OMDA
Q4 2025 - GLP-1 prescribing and AI-driven care are driving growth, efficiency, and expanded market opportunities.OMDA
Evercore ISI 8th Annual HealthCONx Conference